Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials
Identifieur interne : 000D19 ( Istex/Corpus ); précédent : 000D18; suivant : 000D20Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials
Auteurs : Susan E. Sutherland ; George P. BrowmanSource :
- International Journal of Radiation Oncology, Biology, Physics [ 0360-3016 ] ; 2001.
English descriptors
- KwdEn :
- Amifostine, Antibacterial, Antibiotic, Antibiotic lozenges, Basal epithelium, Benzydamine, Biol, Browman, Cancer patients, Carcinoma, Chemotherapy, Chlorhexidine, Clin, Clin oncol, Clinical trial, Clinical trials, Clinician, Control groups, Conventional fractionation, Cytoprotectants, Cytoprotection, Database, Direct cytoprotectants, Drug therapy, Eligibility criteria, Epithelium, Epstein, Fractionation, Head and neck neoplasms, Histology, Indirect cytoprotectants, Irradiation mucositis, Laser, Lozenge, Methodologic, Methodologic quality, Mucosal, Mucositis, Neck cancer, Neck cancer patients, Neck neoplasms, Neck radiotherapy, Neck region, Neck tumors, Oncol, Oncology, Onkol, Oral cavity, Oral complications, Oral mucositis, Oral pathol, Oral surg, Oropharynx, Oropharynx histology, Outcome measures, Overview, Patient assessments, Phys, Placebo, Prophylaxis, Prostaglandin, Quality score, Radiat, Radiat oncol biol phys, Radiation mucositis, Radiation oncology biology physics, Radiation therapy, Radiother oncol, Radiotherapy, Radiotherapy dose, Randomized, Randomized trial, Randomized trials, Reviewer, Seconds subsites, Stomatitis, Strahlenther, Strahlenther onkol, Subgroup, Subgroup analyses, Subgroup analysis, Subsites, Sucralfate, Sucralfate suspension, Surg, Systematic review, Treatment effect, Validity score.
- Teeft :
- Amifostine, Antibacterial, Antibiotic, Antibiotic lozenges, Basal epithelium, Benzydamine, Biol, Browman, Cancer patients, Carcinoma, Chemotherapy, Chlorhexidine, Clin, Clin oncol, Clinical trial, Clinical trials, Clinician, Control groups, Conventional fractionation, Cytoprotectants, Cytoprotection, Database, Direct cytoprotectants, Eligibility criteria, Epithelium, Epstein, Fractionation, Histology, Indirect cytoprotectants, Irradiation mucositis, Laser, Lozenge, Methodologic, Methodologic quality, Mucosal, Mucositis, Neck cancer, Neck cancer patients, Neck neoplasms, Neck radiotherapy, Neck region, Neck tumors, Oncol, Oncology, Onkol, Oral cavity, Oral complications, Oral mucositis, Oral pathol, Oral surg, Oropharynx, Oropharynx histology, Outcome measures, Overview, Patient assessments, Phys, Placebo, Prophylaxis, Prostaglandin, Quality score, Radiat, Radiat oncol biol phys, Radiation mucositis, Radiation oncology biology physics, Radiation therapy, Radiother oncol, Radiotherapy, Radiotherapy dose, Randomized, Randomized trial, Randomized trials, Reviewer, Seconds subsites, Stomatitis, Strahlenther, Strahlenther onkol, Subgroup, Subgroup analyses, Subgroup analysis, Subsites, Sucralfate, Sucralfate suspension, Surg, Systematic review, Treatment effect, Validity score.
Abstract
Abstract: Purpose: To identify, classify, and evaluate agents used in the prophylaxis of oral mucositis in irradiated head and neck cancer patients. Methods: Data sources included multiple databases and manual citation review of relevant literature. Based on the eligibility criteria, 59 studies were independently reviewed by two reviewers. Forty-two studies were included in the classification scheme, of which 15 met the criteria for inclusion in the meta-analysis. Data were extracted by duplicate independent review, with disagreement resolved by consensus. Results: Overall, the interventions reduced the odds of developing severe oral mucositis, when assessed by clinicians, by 36% (OR: 0.64; 95% CI: 0.46, 0.88). Subgroup analysis suggested that only the narrow-spectrum antibacterial lozenges were effective (OR: 0.45; 95% CI: 0.23, 0.86); however, the power of the aggregated data in the other classes may have been insufficient to detect differences. When the outcome was assessed by patients, no significant difference was seen in the outcome between the treatment and the control groups (OR: 0.79; 95% CI: 0.56–1.12). Conclusions: Overall, interventions chosen on a sound biologic basis to prevent severe oral mucositis are effective. In particular, when oral mucositis is assessed by clinicians, narrow-spectrum antibiotic lozenges appear to be beneficial. Methodologic limitations were evident in many of the studies. Further research using validated measurement tools in larger, methodologically sound trials is warranted.
Url:
DOI: 10.1016/S0360-3016(00)01456-5
Links to Exploration step
ISTEX:1AC343C2A2961DFE1F4F5ED37B19635B8E080FFDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials</title><author><name sortKey="Sutherland, Susan E" sort="Sutherland, Susan E" uniqKey="Sutherland S" first="Susan E" last="Sutherland">Susan E. Sutherland</name><affiliation><mods:affiliation>E-mail: susan.sutherland@swchsc.on.ca</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Dentistry, Sunnybrook and Women’s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Browman, George P" sort="Browman, George P" uniqKey="Browman G" first="George P" last="Browman">George P. Browman</name><affiliation><mods:affiliation>The Hamilton Regional Cancer Centre, Cancer Care Ontario, Hamilton, Ontario, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1AC343C2A2961DFE1F4F5ED37B19635B8E080FFD</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S0360-3016(00)01456-5</idno><idno type="url">https://api.istex.fr/document/1AC343C2A2961DFE1F4F5ED37B19635B8E080FFD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000D19</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000D19</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials</title><author><name sortKey="Sutherland, Susan E" sort="Sutherland, Susan E" uniqKey="Sutherland S" first="Susan E" last="Sutherland">Susan E. Sutherland</name><affiliation><mods:affiliation>E-mail: susan.sutherland@swchsc.on.ca</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Dentistry, Sunnybrook and Women’s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Browman, George P" sort="Browman, George P" uniqKey="Browman G" first="George P" last="Browman">George P. Browman</name><affiliation><mods:affiliation>The Hamilton Regional Cancer Centre, Cancer Care Ontario, Hamilton, Ontario, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">International Journal of Radiation Oncology, Biology, Physics</title><title level="j" type="abbrev">ROB</title><idno type="ISSN">0360-3016</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">49</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="917">917</biblScope><biblScope unit="page" to="930">930</biblScope></imprint><idno type="ISSN">0360-3016</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0360-3016</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amifostine</term><term>Antibacterial</term><term>Antibiotic</term><term>Antibiotic lozenges</term><term>Basal epithelium</term><term>Benzydamine</term><term>Biol</term><term>Browman</term><term>Cancer patients</term><term>Carcinoma</term><term>Chemotherapy</term><term>Chlorhexidine</term><term>Clin</term><term>Clin oncol</term><term>Clinical trial</term><term>Clinical trials</term><term>Clinician</term><term>Control groups</term><term>Conventional fractionation</term><term>Cytoprotectants</term><term>Cytoprotection</term><term>Database</term><term>Direct cytoprotectants</term><term>Drug therapy</term><term>Eligibility criteria</term><term>Epithelium</term><term>Epstein</term><term>Fractionation</term><term>Head and neck neoplasms</term><term>Histology</term><term>Indirect cytoprotectants</term><term>Irradiation mucositis</term><term>Laser</term><term>Lozenge</term><term>Methodologic</term><term>Methodologic quality</term><term>Mucosal</term><term>Mucositis</term><term>Neck cancer</term><term>Neck cancer patients</term><term>Neck neoplasms</term><term>Neck radiotherapy</term><term>Neck region</term><term>Neck tumors</term><term>Oncol</term><term>Oncology</term><term>Onkol</term><term>Oral cavity</term><term>Oral complications</term><term>Oral mucositis</term><term>Oral pathol</term><term>Oral surg</term><term>Oropharynx</term><term>Oropharynx histology</term><term>Outcome measures</term><term>Overview</term><term>Patient assessments</term><term>Phys</term><term>Placebo</term><term>Prophylaxis</term><term>Prostaglandin</term><term>Quality score</term><term>Radiat</term><term>Radiat oncol biol phys</term><term>Radiation mucositis</term><term>Radiation oncology biology physics</term><term>Radiation therapy</term><term>Radiother oncol</term><term>Radiotherapy</term><term>Radiotherapy dose</term><term>Randomized</term><term>Randomized trial</term><term>Randomized trials</term><term>Reviewer</term><term>Seconds subsites</term><term>Stomatitis</term><term>Strahlenther</term><term>Strahlenther onkol</term><term>Subgroup</term><term>Subgroup analyses</term><term>Subgroup analysis</term><term>Subsites</term><term>Sucralfate</term><term>Sucralfate suspension</term><term>Surg</term><term>Systematic review</term><term>Treatment effect</term><term>Validity score</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Amifostine</term><term>Antibacterial</term><term>Antibiotic</term><term>Antibiotic lozenges</term><term>Basal epithelium</term><term>Benzydamine</term><term>Biol</term><term>Browman</term><term>Cancer patients</term><term>Carcinoma</term><term>Chemotherapy</term><term>Chlorhexidine</term><term>Clin</term><term>Clin oncol</term><term>Clinical trial</term><term>Clinical trials</term><term>Clinician</term><term>Control groups</term><term>Conventional fractionation</term><term>Cytoprotectants</term><term>Cytoprotection</term><term>Database</term><term>Direct cytoprotectants</term><term>Eligibility criteria</term><term>Epithelium</term><term>Epstein</term><term>Fractionation</term><term>Histology</term><term>Indirect cytoprotectants</term><term>Irradiation mucositis</term><term>Laser</term><term>Lozenge</term><term>Methodologic</term><term>Methodologic quality</term><term>Mucosal</term><term>Mucositis</term><term>Neck cancer</term><term>Neck cancer patients</term><term>Neck neoplasms</term><term>Neck radiotherapy</term><term>Neck region</term><term>Neck tumors</term><term>Oncol</term><term>Oncology</term><term>Onkol</term><term>Oral cavity</term><term>Oral complications</term><term>Oral mucositis</term><term>Oral pathol</term><term>Oral surg</term><term>Oropharynx</term><term>Oropharynx histology</term><term>Outcome measures</term><term>Overview</term><term>Patient assessments</term><term>Phys</term><term>Placebo</term><term>Prophylaxis</term><term>Prostaglandin</term><term>Quality score</term><term>Radiat</term><term>Radiat oncol biol phys</term><term>Radiation mucositis</term><term>Radiation oncology biology physics</term><term>Radiation therapy</term><term>Radiother oncol</term><term>Radiotherapy</term><term>Radiotherapy dose</term><term>Randomized</term><term>Randomized trial</term><term>Randomized trials</term><term>Reviewer</term><term>Seconds subsites</term><term>Stomatitis</term><term>Strahlenther</term><term>Strahlenther onkol</term><term>Subgroup</term><term>Subgroup analyses</term><term>Subgroup analysis</term><term>Subsites</term><term>Sucralfate</term><term>Sucralfate suspension</term><term>Surg</term><term>Systematic review</term><term>Treatment effect</term><term>Validity score</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Purpose: To identify, classify, and evaluate agents used in the prophylaxis of oral mucositis in irradiated head and neck cancer patients. Methods: Data sources included multiple databases and manual citation review of relevant literature. Based on the eligibility criteria, 59 studies were independently reviewed by two reviewers. Forty-two studies were included in the classification scheme, of which 15 met the criteria for inclusion in the meta-analysis. Data were extracted by duplicate independent review, with disagreement resolved by consensus. Results: Overall, the interventions reduced the odds of developing severe oral mucositis, when assessed by clinicians, by 36% (OR: 0.64; 95% CI: 0.46, 0.88). Subgroup analysis suggested that only the narrow-spectrum antibacterial lozenges were effective (OR: 0.45; 95% CI: 0.23, 0.86); however, the power of the aggregated data in the other classes may have been insufficient to detect differences. When the outcome was assessed by patients, no significant difference was seen in the outcome between the treatment and the control groups (OR: 0.79; 95% CI: 0.56–1.12). Conclusions: Overall, interventions chosen on a sound biologic basis to prevent severe oral mucositis are effective. In particular, when oral mucositis is assessed by clinicians, narrow-spectrum antibiotic lozenges appear to be beneficial. Methodologic limitations were evident in many of the studies. Further research using validated measurement tools in larger, methodologically sound trials is warranted.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>mucositis</json:string><json:string>oral mucositis</json:string><json:string>radiotherapy</json:string><json:string>randomized</json:string><json:string>oncol</json:string><json:string>sucralfate</json:string><json:string>antibacterial</json:string><json:string>clin</json:string><json:string>chemotherapy</json:string><json:string>cytoprotectants</json:string><json:string>neck cancer</json:string><json:string>subsites</json:string><json:string>prophylaxis</json:string><json:string>prostaglandin</json:string><json:string>benzydamine</json:string><json:string>oncology</json:string><json:string>biol</json:string><json:string>lozenge</json:string><json:string>amifostine</json:string><json:string>surg</json:string><json:string>chlorhexidine</json:string><json:string>phys</json:string><json:string>radiat</json:string><json:string>oral cavity</json:string><json:string>methodologic</json:string><json:string>subgroup</json:string><json:string>conventional fractionation</json:string><json:string>neck cancer patients</json:string><json:string>stomatitis</json:string><json:string>randomized trial</json:string><json:string>overview</json:string><json:string>placebo</json:string><json:string>clinician</json:string><json:string>browman</json:string><json:string>histology</json:string><json:string>database</json:string><json:string>epithelium</json:string><json:string>onkol</json:string><json:string>strahlenther</json:string><json:string>sucralfate suspension</json:string><json:string>oropharynx</json:string><json:string>methodologic quality</json:string><json:string>laser</json:string><json:string>cytoprotection</json:string><json:string>mucosal</json:string><json:string>clin oncol</json:string><json:string>radiation therapy</json:string><json:string>neck region</json:string><json:string>randomized trials</json:string><json:string>strahlenther onkol</json:string><json:string>outcome measures</json:string><json:string>direct cytoprotectants</json:string><json:string>subgroup analysis</json:string><json:string>oral surg</json:string><json:string>oral pathol</json:string><json:string>neck tumors</json:string><json:string>subgroup analyses</json:string><json:string>radiation oncology biology physics</json:string><json:string>basal epithelium</json:string><json:string>indirect cytoprotectants</json:string><json:string>antibiotic lozenges</json:string><json:string>radiotherapy dose</json:string><json:string>systematic review</json:string><json:string>radiat oncol biol phys</json:string><json:string>radiation mucositis</json:string><json:string>clinical trials</json:string><json:string>treatment effect</json:string><json:string>validity score</json:string><json:string>carcinoma</json:string><json:string>antibiotic</json:string><json:string>fractionation</json:string><json:string>epstein</json:string><json:string>neck radiotherapy</json:string><json:string>quality score</json:string><json:string>radiother oncol</json:string><json:string>clinical trial</json:string><json:string>oral complications</json:string><json:string>seconds subsites</json:string><json:string>oropharynx histology</json:string><json:string>neck neoplasms</json:string><json:string>patient assessments</json:string><json:string>control groups</json:string><json:string>cancer patients</json:string><json:string>eligibility criteria</json:string><json:string>irradiation mucositis</json:string><json:string>reviewer</json:string></teeft></keywords><author><json:item><name>Susan E Sutherland</name><affiliations><json:string>E-mail: susan.sutherland@swchsc.on.ca</json:string><json:string>Department of Dentistry, Sunnybrook and Women’s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada, Toronto, Canada</json:string></affiliations></json:item><json:item><name>George P Browman M.D.</name><affiliations><json:string>The Hamilton Regional Cancer Centre, Cancer Care Ontario, Hamilton, Ontario, Canada</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Head and neck</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Head and neck neoplasms</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Radiotherapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Drug therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Stomatitis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Clinical trials</value></json:item></subject><arkIstex>ark:/67375/6H6-NNGHN9V6-W</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: Purpose: To identify, classify, and evaluate agents used in the prophylaxis of oral mucositis in irradiated head and neck cancer patients. Methods: Data sources included multiple databases and manual citation review of relevant literature. Based on the eligibility criteria, 59 studies were independently reviewed by two reviewers. Forty-two studies were included in the classification scheme, of which 15 met the criteria for inclusion in the meta-analysis. Data were extracted by duplicate independent review, with disagreement resolved by consensus. Results: Overall, the interventions reduced the odds of developing severe oral mucositis, when assessed by clinicians, by 36% (OR: 0.64; 95% CI: 0.46, 0.88). Subgroup analysis suggested that only the narrow-spectrum antibacterial lozenges were effective (OR: 0.45; 95% CI: 0.23, 0.86); however, the power of the aggregated data in the other classes may have been insufficient to detect differences. When the outcome was assessed by patients, no significant difference was seen in the outcome between the treatment and the control groups (OR: 0.79; 95% CI: 0.56–1.12). Conclusions: Overall, interventions chosen on a sound biologic basis to prevent severe oral mucositis are effective. In particular, when oral mucositis is assessed by clinicians, narrow-spectrum antibiotic lozenges appear to be beneficial. Methodologic limitations were evident in many of the studies. Further research using validated measurement tools in larger, methodologically sound trials is warranted.</abstract><qualityIndicators><refBibsNative>true</refBibsNative><abstractWordCount>219</abstractWordCount><abstractCharCount>1538</abstractCharCount><keywordCount>6</keywordCount><score>9.628</score><pdfWordCount>8278</pdfWordCount><pdfCharCount>55804</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>14</pdfPageCount><pdfPageSize>586 x 785 pts</pdfPageSize></qualityIndicators><title>Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials</title><pmid><json:string>11240232</json:string></pmid><pii><json:string>S0360-3016(00)01456-5</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>International Journal of Radiation Oncology, Biology, Physics</title><language><json:string>unknown</json:string></language><publicationDate>2001</publicationDate><issn><json:string>0360-3016</json:string></issn><pii><json:string>S0360-3016(00)X0094-6</json:string></pii><volume>49</volume><issue>4</issue><pages><first>917</first><last>930</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2000</json:string><json:string>2001</json:string><json:string>1966</json:string></date><geogName></geogName><orgName><json:string>University of Toronto</json:string><json:string>Department of Dentistry</json:string><json:string>Department of Dentistry, Suite H</json:string><json:string>Elsevier Science Inc</json:string><json:string>Department of Dentistry, Sunnybrook and Women</json:string><json:string>Department of Clinical Epidemiology and Biostatistics</json:string><json:string>Department of Radiation Oncology, Toronto-Sunnybrook</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Kelly Cottrell</json:string><json:string>Prior</json:string><json:string>The</json:string><json:string>Sixteen</json:string><json:string>Robert MacKenzie</json:string><json:string>Joseph Salvaggio</json:string><json:string>Cochrane</json:string><json:string>Susan E. Sutherland</json:string><json:string>Patsy Kwok</json:string></persName><placeName><json:string>Canada</json:string><json:string>Toronto</json:string></placeName><ref_url></ref_url><ref_bibl></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-NNGHN9V6-W</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - radiology, nuclear medicine & medical imaging</json:string><json:string>2 - oncology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - oncology & carcinogenesis</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Cancer Research</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Radiology Nuclear Medicine and imaging</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Oncology</json:string><json:string>1 - Physical Sciences</json:string><json:string>2 - Physics and Astronomy</json:string><json:string>3 - Radiation</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - otorhinolaryngologie. stomatologie</json:string></inist></categories><publicationDate>2001</publicationDate><copyrightDate>2001</copyrightDate><doi><json:string>10.1016/S0360-3016(00)01456-5</json:string></doi><id>1AC343C2A2961DFE1F4F5ED37B19635B8E080FFD</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/1AC343C2A2961DFE1F4F5ED37B19635B8E080FFD/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/1AC343C2A2961DFE1F4F5ED37B19635B8E080FFD/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/1AC343C2A2961DFE1F4F5ED37B19635B8E080FFD/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>©2001 Elsevier Science Inc.</p></availability><date>2001</date></publicationStmt><notesStmt><note type="content">Section title: Clinical investigation</note><note type="content">Fig. 1: Results of the meta-analysis for the outcome of clinician-assessed severe oral mucositis.</note><note type="content">Fig. 2: Results of the meta-analysis for the outcome of patient-assessed severe oral mucositis.</note><note type="content">Table 1: Criteria for methodologic quality (score)</note><note type="content">Table 2: Agents used to prevent oral mucositis in irradiated head and neck cancer patients: Classification and possible mechanisms of action</note><note type="content">Table 3: Details of the randomized controlled trials of interventions for the prevention of oral mucositislegend</note><note type="content">Table 4: Results for subgroup analysis for severe oral mucositis</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials</title><author xml:id="author-0000"><persName><forename type="first">Susan E</forename><surname>Sutherland</surname></persName><email>susan.sutherland@swchsc.on.ca</email><note type="biography">D.D.S.</note><note type="biography">Reprint requests to: Susan E. Sutherland, D.D.S., Department of Dentistry, Suite H126, Sunnybrook and Women’s College Health Sciences Centre, 2075 Bayview Ave., Toronto, Ontario, Canada M4N 3M5. Tel: (416) 480-4436; Fax: (416) 480-5757</note><affiliation>D.D.S.</affiliation><affiliation>Reprint requests to: Susan E. Sutherland, D.D.S., Department of Dentistry, Suite H126, Sunnybrook and Women’s College Health Sciences Centre, 2075 Bayview Ave., Toronto, Ontario, Canada M4N 3M5. Tel: (416) 480-4436; Fax: (416) 480-5757</affiliation><affiliation>Department of Dentistry, Sunnybrook and Women’s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada, Toronto, Canada</affiliation></author><author xml:id="author-0001"><persName><forename type="first">George P</forename><surname>Browman</surname></persName><roleName type="degree">M.D.</roleName><affiliation>The Hamilton Regional Cancer Centre, Cancer Care Ontario, Hamilton, Ontario, Canada</affiliation></author><idno type="istex">1AC343C2A2961DFE1F4F5ED37B19635B8E080FFD</idno><idno type="DOI">10.1016/S0360-3016(00)01456-5</idno><idno type="PII">S0360-3016(00)01456-5</idno></analytic><monogr><title level="j">International Journal of Radiation Oncology, Biology, Physics</title><title level="j" type="abbrev">ROB</title><idno type="pISSN">0360-3016</idno><idno type="PII">S0360-3016(00)X0094-6</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001"></date><biblScope unit="volume">49</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="917">917</biblScope><biblScope unit="page" to="930">930</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2001</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Purpose: To identify, classify, and evaluate agents used in the prophylaxis of oral mucositis in irradiated head and neck cancer patients. Methods: Data sources included multiple databases and manual citation review of relevant literature. Based on the eligibility criteria, 59 studies were independently reviewed by two reviewers. Forty-two studies were included in the classification scheme, of which 15 met the criteria for inclusion in the meta-analysis. Data were extracted by duplicate independent review, with disagreement resolved by consensus. Results: Overall, the interventions reduced the odds of developing severe oral mucositis, when assessed by clinicians, by 36% (OR: 0.64; 95% CI: 0.46, 0.88). Subgroup analysis suggested that only the narrow-spectrum antibacterial lozenges were effective (OR: 0.45; 95% CI: 0.23, 0.86); however, the power of the aggregated data in the other classes may have been insufficient to detect differences. When the outcome was assessed by patients, no significant difference was seen in the outcome between the treatment and the control groups (OR: 0.79; 95% CI: 0.56–1.12). Conclusions: Overall, interventions chosen on a sound biologic basis to prevent severe oral mucositis are effective. In particular, when oral mucositis is assessed by clinicians, narrow-spectrum antibiotic lozenges appear to be beneficial. Methodologic limitations were evident in many of the studies. Further research using validated measurement tools in larger, methodologically sound trials is warranted.</p></abstract><textClass><keywords scheme="keyword"><list><head>article-category</head><item><term>Head and neck</term></item></list></keywords></textClass><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Head and neck neoplasms</term></item><item><term>Radiotherapy</term></item><item><term>Drug therapy</term></item><item><term>Stomatitis</term></item><item><term>Clinical trials</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2001">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/1AC343C2A2961DFE1F4F5ED37B19635B8E080FFD/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: ce:floats; body; tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"><istex:entity SYSTEM="gr1" NDATA="IMAGE" name="GR1"></istex:entity><istex:entity SYSTEM="gr2" NDATA="IMAGE" name="GR2"></istex:entity></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>ROB</jid><aid>7925</aid><ce:pii>S0360-3016(00)01456-5</ce:pii><ce:doi>10.1016/S0360-3016(00)01456-5</ce:doi><ce:copyright type="full-transfer" year="2001">Elsevier Science Inc.</ce:copyright><ce:doctopics><ce:doctopic><ce:text>Head and neck</ce:text></ce:doctopic></ce:doctopics></item-info><head><ce:dochead><ce:textfn>Clinical investigation</ce:textfn></ce:dochead><ce:title>Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials</ce:title><ce:author-group><ce:author><ce:given-name>Susan E</ce:given-name><ce:surname>Sutherland</ce:surname><ce:roles>D.D.S.</ce:roles><ce:cross-ref refid="AFF1">∗</ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup>†</ce:sup></ce:cross-ref><ce:cross-ref refid="CORR1">*</ce:cross-ref><ce:e-address>susan.sutherland@swchsc.on.ca</ce:e-address></ce:author><ce:author><ce:given-name>George P</ce:given-name><ce:surname>Browman</ce:surname><ce:degrees>M.D.</ce:degrees><ce:cross-ref refid="AFF3"><ce:sup>‡</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF4"><ce:sup>§</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>∗</ce:label><ce:textfn>Department of Dentistry, Sunnybrook and Women’s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada, Toronto, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>†</ce:label><ce:textfn>Department of Dentistry, Toronto-Sunnybrook Regional Cancer Centre, Cancer Care Ontario, Toronto, Ontario, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>‡</ce:label><ce:textfn>The Hamilton Regional Cancer Centre, Cancer Care Ontario, Hamilton, Ontario, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF4"><ce:label>§</ce:label><ce:textfn>Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada</ce:textfn></ce:affiliation><ce:correspondence id="CORR1"><ce:label>*</ce:label><ce:text>Reprint requests to: Susan E. Sutherland, D.D.S., Department of Dentistry, Suite H126, Sunnybrook and Women’s College Health Sciences Centre, 2075 Bayview Ave., Toronto, Ontario, Canada M4N 3M5. Tel: (416) 480-4436; Fax: (416) 480-5757</ce:text></ce:correspondence></ce:author-group><ce:date-accepted day="25" month="9" year="2000"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Purpose: To identify, classify, and evaluate agents used in the prophylaxis of oral mucositis in irradiated head and neck cancer patients.</ce:simple-para><ce:simple-para>Methods: Data sources included multiple databases and manual citation review of relevant literature. Based on the eligibility criteria, 59 studies were independently reviewed by two reviewers. Forty-two studies were included in the classification scheme, of which 15 met the criteria for inclusion in the meta-analysis. Data were extracted by duplicate independent review, with disagreement resolved by consensus.</ce:simple-para><ce:simple-para>Results: Overall, the interventions reduced the odds of developing severe oral mucositis, when assessed by clinicians, by 36% (OR: 0.64; 95% CI: 0.46, 0.88). Subgroup analysis suggested that only the narrow-spectrum antibacterial lozenges were effective (OR: 0.45; 95% CI: 0.23, 0.86); however, the power of the aggregated data in the other classes may have been insufficient to detect differences. When the outcome was assessed by patients, no significant difference was seen in the outcome between the treatment and the control groups (OR: 0.79; 95% CI: 0.56–1.12).</ce:simple-para><ce:simple-para>Conclusions: Overall, interventions chosen on a sound biologic basis to prevent severe oral mucositis are effective. In particular, when oral mucositis is assessed by clinicians, narrow-spectrum antibiotic lozenges appear to be beneficial. Methodologic limitations were evident in many of the studies. Further research using validated measurement tools in larger, methodologically sound trials is warranted.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="keyword"><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Head and neck neoplasms</ce:text></ce:keyword><ce:keyword><ce:text>Radiotherapy</ce:text></ce:keyword><ce:keyword><ce:text>Drug therapy</ce:text></ce:keyword><ce:keyword><ce:text>Stomatitis</ce:text></ce:keyword><ce:keyword><ce:text>Clinical trials</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials</title></titleInfo><name type="personal"><namePart type="given">Susan E</namePart><namePart type="family">Sutherland</namePart><affiliation>E-mail: susan.sutherland@swchsc.on.ca</affiliation><description>D.D.S.</description><affiliation>Department of Dentistry, Sunnybrook and Women’s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada, Toronto, Canada</affiliation><description>Reprint requests to: Susan E. Sutherland, D.D.S., Department of Dentistry, Suite H126, Sunnybrook and Women’s College Health Sciences Centre, 2075 Bayview Ave., Toronto, Ontario, Canada M4N 3M5. Tel: (416) 480-4436; Fax: (416) 480-5757</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">George P</namePart><namePart type="family">Browman</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>The Hamilton Regional Cancer Centre, Cancer Care Ontario, Hamilton, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2001</dateIssued><copyrightDate encoding="w3cdtf">2001</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Purpose: To identify, classify, and evaluate agents used in the prophylaxis of oral mucositis in irradiated head and neck cancer patients. Methods: Data sources included multiple databases and manual citation review of relevant literature. Based on the eligibility criteria, 59 studies were independently reviewed by two reviewers. Forty-two studies were included in the classification scheme, of which 15 met the criteria for inclusion in the meta-analysis. Data were extracted by duplicate independent review, with disagreement resolved by consensus. Results: Overall, the interventions reduced the odds of developing severe oral mucositis, when assessed by clinicians, by 36% (OR: 0.64; 95% CI: 0.46, 0.88). Subgroup analysis suggested that only the narrow-spectrum antibacterial lozenges were effective (OR: 0.45; 95% CI: 0.23, 0.86); however, the power of the aggregated data in the other classes may have been insufficient to detect differences. When the outcome was assessed by patients, no significant difference was seen in the outcome between the treatment and the control groups (OR: 0.79; 95% CI: 0.56–1.12). Conclusions: Overall, interventions chosen on a sound biologic basis to prevent severe oral mucositis are effective. In particular, when oral mucositis is assessed by clinicians, narrow-spectrum antibiotic lozenges appear to be beneficial. Methodologic limitations were evident in many of the studies. Further research using validated measurement tools in larger, methodologically sound trials is warranted.</abstract><note type="content">Section title: Clinical investigation</note><note type="content">Fig. 1: Results of the meta-analysis for the outcome of clinician-assessed severe oral mucositis.</note><note type="content">Fig. 2: Results of the meta-analysis for the outcome of patient-assessed severe oral mucositis.</note><note type="content">Table 1: Criteria for methodologic quality (score)</note><note type="content">Table 2: Agents used to prevent oral mucositis in irradiated head and neck cancer patients: Classification and possible mechanisms of action</note><note type="content">Table 3: Details of the randomized controlled trials of interventions for the prevention of oral mucositislegend</note><note type="content">Table 4: Results for subgroup analysis for severe oral mucositis</note><subject><genre>article-category</genre><topic>Head and neck</topic></subject><subject lang="en"><genre>Keywords</genre><topic>Head and neck neoplasms</topic><topic>Radiotherapy</topic><topic>Drug therapy</topic><topic>Stomatitis</topic><topic>Clinical trials</topic></subject><relatedItem type="host"><titleInfo><title>International Journal of Radiation Oncology, Biology, Physics</title></titleInfo><titleInfo type="abbreviated"><title>ROB</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">20010315</dateIssued></originInfo><identifier type="ISSN">0360-3016</identifier><identifier type="PII">S0360-3016(00)X0094-6</identifier><part><date>20010315</date><detail type="volume"><number>49</number><caption>vol.</caption></detail><detail type="issue"><number>4</number><caption>no.</caption></detail><extent unit="issue-pages"><start>907</start><end>1210</end></extent><extent unit="pages"><start>917</start><end>930</end></extent></part></relatedItem><identifier type="istex">1AC343C2A2961DFE1F4F5ED37B19635B8E080FFD</identifier><identifier type="ark">ark:/67375/6H6-NNGHN9V6-W</identifier><identifier type="DOI">10.1016/S0360-3016(00)01456-5</identifier><identifier type="PII">S0360-3016(00)01456-5</identifier><accessCondition type="use and reproduction" contentType="copyright">©2001 Elsevier Science Inc.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource><recordOrigin>Elsevier Science Inc., ©2001</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/1AC343C2A2961DFE1F4F5ED37B19635B8E080FFD/metadata/json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV2/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D19 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000D19 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= EdenteV2
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1AC343C2A2961DFE1F4F5ED37B19635B8E080FFD
|texte= Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials
}}
| This area was generated with Dilib version V0.6.32. |  |